Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Free Report) – Stock analysts at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for shares of Sandoz Group in a report issued on Tuesday, September 8th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $4.13 per share for the year, up from their prior forecast of $4.10. Erste Group Bank has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.11 per share.
Sandoz Group Price Performance
Shares of SDZNY stock opened at $81.08 on Friday. The business’s 50-day moving average price is $85.00 and its 200-day moving average price is $83.70. Sandoz Group has a 12 month low of $55.42 and a 12 month high of $94.15. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.18 and a quick ratio of 0.77.
About Sandoz Group
Sandoz Group AG is a Switzerland-based pharmaceutical company focused on developing, manufacturing and supplying generic and biosimilar medicines. Its portfolio includes products across areas such as anti-infectives, immunology, oncology, ophthalmology, respiratory care and cardiovascular medicine, as well as injectable and specialty pharmaceuticals.
The company traces its origins to Sandoz, founded in Basel in 1886, and became an independent business through its separation from Novartis in 2023.
Featured Articles
- Five stocks we like better than Sandoz Group
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
